All In Biotech

Drug Trial Radar · NCT07342478

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

306

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Oct 30, 2029

Study completion Jul 30, 2030

Sponsor

Lead sponsor
Newave Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.

Conditions

  • CLL / SLL
  • CLL (Chronic Lymphocytic Leukemia)
  • CLL, Refractory
  • CLL, Relapsed
  • SLL (Small Lymphocytic Lymphoma)
  • SLL
  • CLL
  • CLL Progression

Interventions

  • RocbrutinibDrug

    The new generation, highly potent, ultra-selective BTK inhibitor with covalent and non-covalent dual binding mechanism, targeting both WT BTK and mutant BTK

  • PirtobrutinibDrug

    Pirtobrutinib is a non-covalent BTK inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS assessed by IRCTime frame: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Orchard Healthcare Research

    Skokie, Illinois · Recruiting

  • The Center for Cancer and Blood Disorders-Bethesda

    Bethesda, Maryland · Recruiting

  • Optum Medical Group (Rhodes) P.C.

    Las Vegas, Nevada · Recruiting

  • Duke Adult Blood and Marrow Clinic

    Durham, North Carolina · Recruiting

  • OSU Comprehensive Cancer Center

    Columbus, Ohio · Not yet recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Medical Oncology Associates - Spokane

    Spokane, Washington · Recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre Hospitalier Le Mans

    Le Mans, France · Recruiting

  • CHRU Tours Bretonneau

    Tours, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.